CTOs on the Move

Johnson & Johnson Vision

www.jjvision.com

 
Learn about how Johnson & Johnson Vision is committed to addressing the world-wide problems of vision impairment through prevention and treatment.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.jjvision.com
  • 7500, Centurion Parkway North
    Jacksonville, FL USA 32256
  • Phone: 904.443.1000

Executives

Name Title Contact Details

Similar Companies

UltraFiltronics Corp

UltraFiltronics Corp is a Randolph, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.

Quotient Bioresearch

Quotient Bioresearch is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

miraDry

Make excessive sweat a thing of the past. Learn how miraDry® can permanently reduce underarm sweat in as little as one non-surgical treatment.